Epinastine
| Evidence Level: L5 | Predicted Indications: 2 |
Table of Contents
Epinastine: From Allergic Conjunctivitis to Rosacea Conjunctivitis
One-Sentence Summary
Epinastine is a topical antihistamine originally used to treat allergic conjunctivitis (atopic, papillary and vernal forms). The TxGNN model predicts it may be effective for Rosacea Conjunctivitis, but no clinical trials and no publications currently support this specific prediction, so it rests on model output alone.
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Atopic conjunctivitis, papillary conjunctivitis, vernal conjunctivitis |
| Predicted New Indication | Rosacea conjunctivitis |
| TxGNN Prediction Score | 0.9957 |
| Evidence Level | L5 |
| India Market Status | Listed in a compiled Indian medicine price dataset (4 of 4) – CDSCO approval status is not included in this data |
| Number of Listed Products | 4 (valid: 4) |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data is not available in the data compiled for this report. Based on known information, epinastine is a topical H1 receptor antagonist with mast cell stabilising activity. Its efficacy in allergic conjunctivitis is established, and it may be mechanistically applicable to other inflammatory conditions of the ocular surface.
The link to rosacea conjunctivitis is only a partial fit. Epinastine could relieve itching and surface inflammation. However, ocular disease in rosacea is driven mainly by meibomian gland dysfunction, eyelid inflammation, and microbial or Demodex factors, rather than classic IgE-mediated histamine release. The very high model score (0.9957) therefore cannot be confirmed mechanistically at this stage.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available for rosacea conjunctivitis.
For reference, the second-ranked prediction, allergic urticaria, has indirect literature on epinastine’s antihistamine pharmacology (for example, PMID 10442525, a 1999 double-blind crossover study of histamine-induced wheal and flare suppression in healthy volunteers). This does not support the rosacea conjunctivitis prediction.
India Market Information
| Authorization Number | Product Name | Dosage Form | Approved Indication |
|---|---|---|---|
| 189485 | Relestat Ophthalmic Solution (Allergan India Pvt Ltd) | 5 ml ophthalmic solution | Not specified |
| 74323 | Estina Eye Drop (Entod Pharmaceuticals Ltd) | 5 ml eye drop | Not specified |
| 80560 | Eparto Eye Drop (Neiss Labs Pvt Ltd) | 5 ml eye drop | Not specified |
| 73608 | Epitane Eye Drop (Micro Labs Ltd) | 5 ml eye drop | Not specified |
All four registrations are valid single-ingredient ophthalmic products, so the route of administration is already suited to an ocular indication.
Safety Considerations
Please refer to the package insert for safety information.
Conclusion and Next Steps
Decision: Hold
Rationale: The prediction is supported only by the model score. No trials or literature were found, and the antihistamine mechanism fits rosacea-related ocular disease only partly. The drug is already marketed in India as an eye drop, which would ease any future study.
To proceed, the following is needed:
- A targeted literature and trial search on antihistamines or mast cell stabilisers in ocular rosacea and meibomian gland dysfunction
- Mechanism of action data to assess the biological link
- Package insert warnings and contraindications for the marketed Indian products, to complete safety screening
- Approved indication text for the Indian registrations
- If the hypothesis still looks credible, a small exploratory study that measures symptoms such as itching and eyelid inflammation
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.